PMID- 11075394
OWN - NLM
STAT- MEDLINE
DCOM- 20001128
LR  - 20190826
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21
IP  - 10
DP  - 2000 Oct
TI  - [Anti-TNF-alpha monoclonal antibodies in the treatment of rheumatoid arthritis].
PG  - 854-62
AB  - INTRODUCTION: Current slow-acting anti-rheumatic drugs available for rheumatoid 
      arthritis can fail for certain severe cases; some are used empirically. 
      Improvements in our knowledge of its pathogenesis and advances in molecular 
      biology have made it possible to develop partially selective immunotherapy 
      approaches. CURRENT KNOWLEDGE AND KEY POINTS: Tumor necrosis factor-alpha 
      (TNF-alpha) is a critical inflammatory mediator in rheumatoid arthritis and may 
      therefore be a useful target for specific immunotherapy. This article summarizes 
      clinical studies using anti-TNF-alpha antibodies. It appears that there is good 
      evidence for both safety and beneficial effects of anti-TNF-alpha antibodies in 
      short-term treatment of rheumatoid arthritis. FUTURE PROSPECTS AND PROJECTS: It 
      remains to be determined whether specific blockade of a single inflammatory 
      mediator may be useful in long-term management. Therapeutic strategies aimed at 
      concomitantly interfering with multiple pathogenic pathways are currently under 
      investigation.
FAU - Mugnier, B
AU  - Mugnier B
AD  - Service de rhumatologie, hopital de la Conception, Marseille, France.
FAU - Bouvenot, G
AU  - Bouvenot G
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Les anticorps monoclonaux anti-TNF-alpha dans le traitement de la polyarthrite 
      rhumatoide.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 1V3N66A87N (CDP 571)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Antibodies, Monoclonal/immunology/*therapeutic use
MH  - Antirheumatic Agents/immunology/*therapeutic use
MH  - Arthritis, Rheumatoid/immunology/*therapy
MH  - Humans
MH  - Immunotherapy/methods
MH  - Infliximab
MH  - Research Design
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
RF  - 43
EDAT- 2000/11/15 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/15 11:00
PHST- 2000/11/15 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/15 11:00 [entrez]
AID - S0248866300002368 [pii]
AID - 10.1016/s0248-8663(00)00236-8 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Oct;21(10):854-62. doi: 10.1016/s0248-8663(00)00236-8.